|Dr. Wilfred A. Jefferies||Co-Founder, Chairman & Chief Science Officer||N/A||N/A||1958|
|Dr. Lyle Oberg M.D.||Co-Founder, CEO & Director||N/A||N/A||1960|
|Mr. Lih-Ming Tam||Interim CFO & Sr. Controller||N/A||N/A||N/A|
|Dr. Chaahat S.B Singh||Sr. Operations & Research Mang.||N/A||N/A||N/A|
|Mr. Luke Warkentin||VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Iryna Saranchova Ph.D.||Chief Clinical Officer||N/A||N/A||N/A|
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company was incorporated in 2018 and is headquartered in Kelowna, Canada.
MYND Lifesciencs Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.